Beyond Borders PDF Download

Author: National Research Council
Publisher: National Academies Press
ISBN: 0309134285
Category : Computers
Languages : en
Pages : 386

View

Book Description
The debate over offshoring of production, transfer of technological capabilities, and potential loss of U.S. competitiveness is a long-running one. Prevailing thinking is that "the world is flat"â€"that is, innovative capacity is spreading uniformly; as new centers of manufacturing emerge, research and development and new product development follow. Innovation in Global Industries challenges this thinking. The book, a collection of individually authored studies, examines in detail structural changes in the innovation process in 10 service as well as manufacturing industries: personal computers; semiconductors; flat-panel displays; software; lighting; biotechnology; pharmaceuticals; financial services; logistics; and venture capital. There is no doubt that overall there has been an acceleration in global sourcing of innovation and an emergence of new locations of research capacity and advanced technical skills, but the patterns are highly variable. Many industries and some firms in nearly all industries retain leading-edge capacity in the United States. However, the book concludes that is no reason for complacency about the future outlook. Innovation deserves more emphasis in firm performance measures and more sustained support in public policy. Innovation in Global Industries will be of special interest to business people and government policy makers as well as professors, students, and other researchers of economics, management, international affairs, and political science.

Author: DIANE Publishing Company
Publisher: DIANE Publishing
ISBN: 9780941375603
Category : Science
Languages : en
Pages : 294

View

Book Description

Author:
Publisher:
ISBN:
Category : Biotechnology
Languages : en
Pages : 102

View

Book Description

Author:
Publisher:
ISBN:
Category : Biotechnology
Languages : en
Pages : 36

View

Book Description

Author: Prabuddha Ganguli
Publisher: John Wiley & Sons
ISBN: 3527627316
Category : Science
Languages : en
Pages : 232

View

Book Description
Here, the world's top experts impart their knowledge and experience, many in print for the first time. By considering developing country markets, this book is the first truly global guide to technology transfer, helping companies all around the world to avoid costly mistakes in product development and to recover investments quickly. Individual sections treat trade-related aspects of intellectual property rights, technology transfer in health and healthcare as well as in agriculture and the environment.

Author: Alan M. Russell
Publisher: Manchester University Press
ISBN: 9780719058684
Category : Medical
Languages : en
Pages : 276

View

Book Description
There are three sections. The first considers the nature of the science itself, the normative questions rasied and the significance of gender responses. Following these broad issues, the second section addresses biotechnology in relation to international policial economy, trade and the environment, highlighting the politics of food and patents. The final section tackles the question of biological knowledge applied to weapons and the global responses.

Author: National Research Council
Publisher: National Academies Press
ISBN: 0309316553
Category : Science
Languages : en
Pages : 158

View

Book Description
The tremendous progress in biology over the last half century - from Watson and Crick's elucidation of the structure of DNA to today's astonishing, rapid progress in the field of synthetic biology - has positioned us for significant innovation in chemical production. New bio-based chemicals, improved public health through improved drugs and diagnostics, and biofuels that reduce our dependency on oil are all results of research and innovation in the biological sciences. In the past decade, we have witnessed major advances made possible by biotechnology in areas such as rapid, low-cost DNA sequencing, metabolic engineering, and high-throughput screening. The manufacturing of chemicals using biological synthesis and engineering could expand even faster. A proactive strategy - implemented through the development of a technical roadmap similar to those that enabled sustained growth in the semiconductor industry and our explorations of space - is needed if we are to realize the widespread benefits of accelerating the industrialization of biology. Industrialization of Biology presents such a roadmap to achieve key technical milestones for chemical manufacturing through biological routes. This report examines the technical, economic, and societal factors that limit the adoption of bioprocessing in the chemical industry today and which, if surmounted, would markedly accelerate the advanced manufacturing of chemicals via industrial biotechnology. Working at the interface of synthetic chemistry, metabolic engineering, molecular biology, and synthetic biology, Industrialization of Biology identifies key technical goals for next-generation chemical manufacturing, then identifies the gaps in knowledge, tools, techniques, and systems required to meet those goals, and targets and timelines for achieving them. This report also considers the skills necessary to accomplish the roadmap goals, and what training opportunities are required to produce the cadre of skilled scientists and engineers needed.

Author: Donald L. Drakeman
Publisher: Oxford University Press
ISBN: 0195084004
Category : Biotechnology industries
Languages : en
Pages : 241

View

Book Description
"Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. How could a large collection of small companies, most with fewer than 50 employees, compete in one of the world's most breathtakingly expensive and highly regulated industries? This book shows how biotech companies have met the challenge by creating nearly 40% more of the most important treatments for unmet medical needs. Moreover, they have done so with much lower overall costs. The book focuses on both the companies themselves and the broader biotech ecosystem that supports them. Its portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies shows how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions. Looking to the future, it concludes that biomedical research will continue to be most effective in the hands of a large group of small companies as long as national healthcare policies allow the rest of the ecosystem to continue to thrive"--

Author: Ajit Pandya
Publisher:
ISBN: 9781517064822
Category :
Languages : en
Pages : 106

View

Book Description
With the slew of biotechnology related events and news of late, the common man's curiosity and interest in a simple technical analysis of biotechnology have been sufficiently whetted. The ball was set in motion with the completion of the Human Genome Project in 2000. This was followed concurrently by other technological and on-the-ground developments such as the commercialization and cultivation of Genetically Modified (GM) crops.Global Scenario:According to a research report by Ernst & Young titled Beyond Borders 2002, the global biotech industry comprised of 4,284 companies (622 public; 3,6662 private) in 25 nations. The 622 public companies have generated revenues of $35 bn, spent $16 bn on R&D and employed more than 188,000 people. US biotech companies roughly account for 70% of the total global revenues of biotech industry but other regions are growing at a fast pace too. Biotech sectors in Europe, Canada and the Asia-Pacific region have experienced significant growth in the number of companies due to advancements in technologies, which are mining their way from research labs to full fledged commercialized enterprises. It was estimated that by 2005, the European biotech market could double to more than $100 bn. This growth has led the companies and experienced investors to look beyond the borders of their own countries in search of promising technologies, talented people and new markets. Biotech is an emerging sector in Asia-Pacific, which is experiencing considerable expansion in countries such as Australia, china, India and Singapore with the presence of around 500 biotech companies.Indian Biotech Industry:In the global biotech market, the current share of India is just about 2%; however, the future seems very bright as biotechnology is a fast emerging sector in the country. The Association of Biotech Led Enterprises (ABLE) pegs the Indian biotech market, including biosuppliers, Rs. 23.05 bn in the year 2002-03. The market size is estimated to be Rs. 18.30 bn if biosuppliers are excluded. The market is divided among the Bioindustrial, Bioservice, Bioagriculgture, Bioinformatics and Biosuppliers. Shantha Biotech was the first in India to launch an indigenous recombinant product called Shanvac-B (hepatitis-B vaccine) in 1997. Other players in this are included Biocon Bharat biotech, Bharat serums, Biological E Hlffkine Bio-Pharmaceutical, Panacea, Pfizer, Serum Institute of India, SmithKline Beecham and Wokhardt.

Author: Ajit Pandya
Publisher: CreateSpace
ISBN: 9781517056841
Category :
Languages : en
Pages : 100

View

Book Description
With the slew of biotechnology related events and news of late, the common man's curiosity and interest in a simple technical analysis of biotechnology have been sufficiently whetted. The ball was set in motion with the completion of the Human Genome Project in 2000. This was followed concurrently by other technological and on-the-ground developments such as the commercialization and cultivation of Genetically Modified (GM) crops. Global Scenario: According to a research report by Ernst & Young titled Beyond Borders 2002, the global biotech industry comprised of 4,284 companies (622 public; 3,6662 private) in 25 nations. The 622 public companies have generated revenues of $35 bn, spent $16 bn on R&D and employed more than 188,000 people. US biotech companies roughly account for 70% of the total global revenues of biotech industry but other regions are growing at a fast pace too. Biotech sectors in Europe, Canada and the Asia-Pacific region have experienced significant growth in the number of companies due to advancements in technologies, which are mining their way from research labs to full fledged commercialized enterprises. It was estimated that by 2005, the European biotech market could double to more than $100 bn. This growth has led the companies and experienced investors to look beyond the borders of their own countries in search of promising technologies, talented people and new markets. Biotech is an emerging sector in Asia-Pacific, which is experiencing considerable expansion in countries such as Australia, china, India and Singapore with the presence of around 500 biotech companies. Indian Biotech Industry: In the global biotech market, the current share of India is just about 2%; however, the future seems very bright as biotechnology is a fast emerging sector in the country. The Association of Biotech Led Enterprises (ABLE) pegs the Indian biotech market, including biosuppliers, Rs. 23.05 bn in the year 2002-03. The market size is estimated to be Rs. 18.30 bn if biosuppliers are excluded. The market is divided among the Bioindustrial, Bioservice, Bioagriculgture, Bioinformatics and Biosuppliers. Shantha Biotech was the first in India to launch an indigenous recombinant product called Shanvac-B (hepatitis-B vaccine) in 1997. Other players in this are included Biocon Bharat biotech, Bharat serums, Biological E Hlffkine Bio-Pharmaceutical, Panacea, Pfizer, Serum Institute of India, SmithKline Beecham and Wokhardt.